pre-update Archives

Publication

Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics

Perhaps the most important lesson learned from the COVID‐19 pandemic is that of preparedness. Enhanced…

CertaraMay 11, 2021

Brochure

Early Engagement with HTA Bodies

In-depth guide to successful early HTA engagement.

CertaraMay 10, 2021

On-Demand Webinar

Evidence generation in Europe- How valuable is the French National administrative health data (SNDS)

Watch this presentation to learn • Overview of the SNDS and the key working practices…

CertaraMay 7, 2021

Blog

Maximizing Oligonucleotide Therapeutic Development: How They Work

This is the first of three blog posts discussing best practices for developing oligonucleotides. Interest…

CertaraMay 7, 2021

On-Demand Webinar

The Wizard of Oligos: There’s no place like having a successful drug development program!

Oligonucleotide therapies— nucleic acid polymers with the potential to treat or manage a wide range…

CertaraApril 30, 2021

On-Demand Webinar

The Promises and Pitfalls of Gene Therapy for Rare Diseases

The state of gene therapy faces much uncertainty as recent regulatory and clinical setbacks have…

CertaraApril 29, 2021

Fact Sheet

Regulatory Writing

Expert Writing. Faster Approvals. Read our Regulatory Writing Factsheet

CertaraApril 28, 2021

Fact Sheet

Anonymization and Redaction

CertaraApril 28, 2021

Fact Sheet

Transparency and Disclosure

CertaraApril 28, 2021

Fact Sheet

Regulatory Consulting and Regulatory Affairs

CertaraApril 28, 2021

pre-update

Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics

Early Engagement with HTA Bodies

Evidence generation in Europe- How valuable is the French National administrative health data (SNDS)

Maximizing Oligonucleotide Therapeutic Development: How They Work

The Wizard of Oligos: There’s no place like having a successful drug development program!

The Promises and Pitfalls of Gene Therapy for Rare Diseases

Regulatory Writing

Anonymization and Redaction

Transparency and Disclosure

Regulatory Consulting and Regulatory Affairs

Newsletter sign up

Quick links

Solutions

Contact